VAR - Varian Medical Systems Company Profile

Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through two segments, Oncology Systems and Imaging Components. The Oncology Systems segment provides hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy. Its products include linear accelerators, brachytherapy afterloaders, treatment simulation, verification equipment, and accessories; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, oncology practices, radiotherapy centers, and cancer care clinics. The Imaging Components segment offers X-ray imaging components for use in radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography, computer aided diagnostics, and industrial applications. It also provides Linatron X-ray accelerators, imaging processing software, and image detection products for security and inspection purposes. This segment serves original equipment manufacturers, independent service companies, and end-users. In addition, the company offers products and systems for delivering proton therapy; and develops technologies in the areas of digital X-ray imaging, volumetric and functional imaging, and improved X-ray sources. Company description from

Expected earnings October 25th.

Varian reported earnings of $1.04 that beat estimates for 95 cents. Revenue of $662.4 million just barely missed estimates for $663.2 million due in part to currency translation issues. They sell their high dollar imaging systems all over the world.

The guided for the current quarter for earnings of $1.15-$1.23 and analysts were expecting $1.18. This should have been positive but the stock fell $6 because of the minor revenue miss.

Shares had rebounded to a new high at $107.87 on Sept 14th but ran into a bout of profit taking that knocked it back to $98. There was no news that would have been negative. It was simply time for portfolio managers to rotate into something else for the next earnigns cycle.

Varian just announced the initial treatments of cancer patients using their new Halcyon radiation system. The first patient had head and neck cancer that required delivery of the treatment to nine different locations. The entire treatment time including setup, imaging, 3 minutes of beam time and patient discharge was only 13 minutes. Typically, a treatment like this using other technology requires 10 minutes of beam time and 20 min of total treatment time, plus it is far less precise.

Varian is delivering state of the art radiation systems all over the world and they are the leading edge in this technology.

The recent decline has taken VAR back to uptrend support and I believe it is time to buy the dip.

Varian does not have LEAPS so I am using the longest dated option available for May 2018.

*** Use a LIMIT order for $4.75 ***
Buy May $105 call, currently $4.60, initial stop loss $93.75.